H.C. Wainwright has increased its price target for BioXcel Therapeutics (BTAI, Financial), moving it up to $8 from the previous $3, while maintaining a Buy rating on the stock. This adjustment comes after the firm evaluated the effects of the most recent equity financing conducted in March and considered the February reverse stock split. These financial maneuvers have influenced the new valuation, reflecting the firm's continued confidence in BTAI’s potential.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for BioXcel Therapeutics Inc (BTAI, Financial) is $17.40 with a high estimate of $48.00 and a low estimate of $1.00. The average target implies an upside of 948.19% from the current price of $1.66. More detailed estimate data can be found on the BioXcel Therapeutics Inc (BTAI) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, BioXcel Therapeutics Inc's (BTAI, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
